Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement
Anti-Cancer Drugs, cilt.33, sa.4, ss.400-405, 2022 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 33 Sayı: 4
- Basım Tarihi: 2022
- Doi Numarası: 10.1097/cad.0000000000001272
- Dergi Adı: Anti-Cancer Drugs
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Biotechnology Research Abstracts, CAB Abstracts, Chemical Abstracts Core, EMBASE, MEDLINE, Veterinary Science Database
- Sayfa Sayıları: ss.400-405
- Anahtar Kelimeler: alk fusion, breast cancer, crizotinib, treatment, triple-negative
- Trakya Üniversitesi Adresli: Evet
Özet
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3-5% of non-small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens the door to new treatment strategies.